

Personal Information:

NAME:

Delaram Doroud, Pharm D



ADDRESS:

Molecular Immunology and Vaccine Research Laboratory, Dept. of Immunology, Pasteur Institute of Iran, Tehran, Iran 13164

Tel: 0098 21 695 3311-20 Ext. 2112/2115

Fax: 0098 21 874 2314

E-mail: doroud@razi.tums.ac.ir , delaramdoroud@yahoo.com

PRESENT AND PREVIOUS POSITIONS:

2006-present PhD student

2005-2008 Documentation and Batch Release Head in Quality Assurance Department

2000-2005 Researcher, Biotechnology Department, Pasteur Institute of Iran

EDUCATION & COURSES:

2006-Present PhD Student of Pharmaceutical Sciences, Faculty of Pharmacy, Tehran University of Medical Sciences

Thesis: Preparation and Evaluation of solid lipid nanoparticle-*cystein proteinase* gene vector as a *Leishmania* vaccine novel formulation

Supervisors : Prof. Sima Rafati, Dr. Rouholamini Najafabadi

Abstract: Although DNA vaccination offers appropriate promises against experimental leishmaniasis, free plasmid DNA clinical utility is still faced with a number of significant hurdles. Thus an appropriate vaccine formulation offers good opportunities to increase vaccine efficacy. In this view, various colloidal carrier systems have been extensively studied for the formulation of DNA vaccines. Amongst these, Solid Lipid Nanoparticles (SLN[®]) are offered to be a promising alternative to the polymeric nanoparticles and liposomes. In continuation of *Leishmania* vaccine studies, we are attempting to prepare SLN-pDNA complexes as a vaccine formulation using cysteine proteinases type I, II and III.

2005 Documentation Course Hepatitis B Project, Technology Transfer (by Cuban Specialists)

2005 Batch Release Course WHO

2005 QA in the Pharmaceutical Industry By NRA

1994- 1998 Pharmacy, Azad University, Tehran , Iran

THESIS: Synthesis and Evaluation of the Anticuculsant Effects of New GABA Prodrugs

Supervised By: Dr. Ali Khalaj and Dr. Mohammad Hussein Pourgholami

=====➔

CATEGORY OF RESEARCH

Nanobiotechnology
Medical Biotechnology

=====➔

SKILLS AND RESEARCH AREAS:

- GMP Implementation in Pharmaceutical and Biopharmaceutical Industry
- Drug and Gene Delivery
- Nanoparticle Synthesis
- Helicobacter pylori
- ✓ Cloning and expression of recombinant proteins
- ✓ Molecular Genotyping and Phenotyping
- ✓ PCR
- ✓ RAPD-PCR
- ✓ PCR-RFLP
- ✓ 2-DE
- Pharmaceutical Chemistry: Synthesis of the GABA mimetic Substances

=====➔

PARTICIPATE IN THE FOLLOWING ACTIVE RESEARCH PROJECTS AND GRANTS:

- PCR-RFLP analysis of conserved and non-conserved genes of *Helicobacter pylori* strains isolated from Iranian dyspeptic patients.
- ✓ Funded by: **Societe de Pathologie Exotique, Paris, France. 2000**
- Evaluation of antibiotic resistance in *Helicobacter pylori* via molecular assays
- ✓ Funded by: **Pasteur Institute of Iran, Tehran, Iran. 2003**

=====➔

PUBLICATIONS/SEMINARS/PATENTS: (Start from most recent)

- ❖ M. Mohammadi, **D. Doroud**, HP Research Group, Clinical Team, H. R. Vaziri, A. Abdi., M. Mohagheghi. Colloque Scientifique du Reseau International des Instituts Pasteur. Alger 16-17 Nov **2005**.
- ☒ M. Mohammadi, **D. Doroud**, N. Mohajerani, S. Massarrat. **2005**. Helicobacter pylori Antibiotic Resistance in Iran. World J Gastroenterol;11(38):6009-6013.
As Co First Author.
- ☒ "محمد رضا بابايي مقدم و دلارام درود" مطالعه اثربخشي اتانل به عنوان عامل موثر در کوتاه نمودن زمان رشد مايكوباكتريوم توبركلوزيس در محيط كشت. مجله بيماريهاي عفوني و گرمسيري شماره 18 سال 7 . 1381-
- ❖ **D. Doroud**, M. Mohammadi, L. Zamaninia, M. Feizabadi, H. Colding, and L.P. Andersen. **2005**. Determination of genetic diversity among Iranian and Danish

strains of *Helicobacter pylori* via RAPD-PCR fingerprinting. *Helicobacter*;10 (5):468.

- ❖ **D. Doroud**, M. Mohammadi, Y. Talebkhan, L. Zamaninia, H. R. Vaziri, M. A. Mohagheghi, M. Ghaffarpour, N. Mohajerani, and A. Nahvijoo. **2005**. Determination of single versus multi-strain infection in gastric cancer versus noncancer patients by microbiologic mapping and fingerprinting of *Helicobacter pylori* via RAPD-PCR fingerprinting. *Helicobacter*;10 (5):469.
- ❖ Oghalaie A. **D. Doroud** , HP Research Group, M. Eshagh Hosseini, G. R. Habibi, Clinical Team, M. A. Mohagheghi and **M. Mohammadi**. **2005**. Molecular detection of host cytokine expression in cancer and non-cancer *Helicobacter pylori* patients via semi-quantitative RT-PCR. Fourth National Biotechnology Congress. P. 25.
- ❖ Ghaffarpour M., **D. Doroud** , HP Research Group, M. A. Mohagheghi, H.R. Vaziri, Clinical Team, and **M. Mohammadi**. **2005**. Genotyping and phenotyping *Helicobacter pylori* virulence markers in Iranian gastric cancer and non gastric cancer patients. Fourth National Biotechnology Congress. P. 28.
- ❖ **Doroud D.**, HP Research Group, Clinical Team, H.R. Vaziri, M. A. Mohagheghi and **M. Mohammadi**. **2005**. Determination of single vs. multi-strain infection in gastric cancer vs. non-cancer patients by microbiologic mapping and finger printing. Fourth National Biotechnology Congress. P. 24.
- ❖ Zohari M., **D. Doroud** HP Research Group, Clinical Team, H.R. Vaziri, M. A. Mohagheghi and **M. Mohammadi**. **2005**. Association between pro-inflammatory cytokine gene polymorphism and increased risk of gastric cancer. Fourth National Biotechnology Congress. P. 27.
- ❖ **Doroud, D.**, N. Mohajerani, S. Massarrat, and **M. Mohammadi**. **2005**. Are molecular methods appropriate substitutions for traditional antimicrobial assays in detecting *Helicobacter pylori* antibiotic resistance in Iranian clinical trials? Fourth National Biotechnology Congress. P. 303.
- ❖ A. Oghalaie, **D. Doroud** , HP Research Group, Clinical Team, M. Eshagh Hosseini, M. A. Mohagheghi and **M. Mohammadi**. **2005**. Cytokine gene expression in gastric cancer patients via semi-quantitative RT-PCR. Third Regional Conference of Asian Pacific Organization for Cancer Prevention (APOCP) GI Cancer Control. P. 70.
- ❖ M. Ghaffarpour, **D. Doroud** , HP Research Group, Clinical Team, M. H. R. Vaziri, M. A. Mohagheghi and **M. Mohammadi**. **2005**. Evaluation of Host Response toward *Helicobacter pylori* antigens in gastric adenocarcinoma patients; Significance of anti-CagA and VacA antibodies. Third Regional Conference of Asian Pacific Organization for Cancer Prevention (APOCP) GI Cancer Control. P. 59-60.
- ❖ Y. Talebkhan, N. Mohajerani, **D. Doroud** , HP Research Group, Clinical Team, H.R. Vaziri, M. A. Mohagheghi and **M. Mohammadi**. **2005**. Risk factors in the pathogenesis of gastric cancer among Iranian population. Third Regional

- Conference of Asian Pacific Organization for Cancer Prevention (APOCP) GI Cancer Control. P. 76-77.
- ❖ **D. Doroud**, HP Research Group, Clinical Team, H.R. Vaziri, M. A. Mohagheghi and **M. Mohammadi**. **2005**. Determination of single vs. multi-strain infection in gastric cancer vs. non-cancer patients by microbiologic mapping and finger printing. Third Regional Conference of Asian Pacific Organization for Cancer Prevention (APOCP) GI Cancer Control. P. 141-142.
 - ❖ Y. Talebkhan, **D. Doroud**, HP Research Group, Clinical Team, H.R. Vaziri, M. A. Mohagheghi and **M. Mohammadi**. **2005**. Is pepsinogen I a reliable marker for prognosis of gastric cancer among Iranian population. Third Regional Conference of Asian Pacific Organization for Cancer Prevention (APOCP) GI Cancer Control. P. 178.
 - ❖ Y. Talebkhan, **D. Doroud**, HP Research Group, Clinical Team, H.R. Vaziri, M. A. Mohagheghi and **M. Mohammadi**. **2005**. Detection of predominant *Helicobacter pylori* genotypes among Iranian gastric cancer and non gastric cancer patients. Third Regional Conference of Asian Pacific Organization for Cancer Prevention (APOCP) GI Cancer Control. P. 179-180.
 - ❖ L. Zamaninia, **D. Doroud**, HP Research Group, Clinical Team, H.R. Vaziri, M. A. Mohagheghi and **M. Mohammadi**. **2005**. Pattern of *Helicobacter pylori* colonization in the gastric epithelium of gastric cancer and non cancer patients. Third Regional Conference of Asian Pacific Organization for Cancer Prevention (APOCP) GI Cancer Control. P. 186-187.
 - ❖ M. Zohari, **D. Doroud**, HP Research Group, Clinical Team, H.R. Vaziri, M. A. Mohagheghi and **M. Mohammadi**. **2005**. Association between pro-inflammatory cytokine gene polymorphism and increased risk of gastric cancer. Third Regional Conference of Asian Pacific Organization for Cancer Prevention (APOCP) GI Cancer Control. P. 188-189.
 - ❖ **M. Mohammadi**, **Delaram Doroud**, Nazanin Mohajerani, Leili Zamaninia, and Leif Percival Andersen. **2004**. Correlation of the *rdxA* gene deletion and metronidazole resistance in Iranian *Helicobacter pylori* strains. Sixth International conference on pathogenesis and host response in *Helicobacter* infection. Helsingor, Denmark. *Oral presentation*. P:31
 - ☒ **M. Mohammadi**, **D. Doroud**, S. Massarrat, M. Farahvash. **2003**. Clarithromycin Resistance in Iranian *Helicobacter pylori* Strains; *Helicobacter*; 8(1):80.
 - ❖ **M. Mohammadi**, **D. Doroud**, N. Mohajerani, A. Oghalaie, S. Massarrat, M. Farahvash. **2003**. Clarithromycin Resistance in Iranian *Helicobacter pylori* Strains; Is it a Drug of Choice for Iran? *Helicobacter*; 8(4):471.
 - ❖ **M. Mohammadi**, **D. Doroud**, L. Zamaninia, S. Massarrat, H. Colding, L. P. Andersen. **2003**. Molecular analysis of *Helicobacter pylori* using RAPD-PCR fingerprinting to determine genetic diversity between Iranian and Danish strains. *Helicobacter*;8(4):396.

- ❖ **D. Doroud**, N. Mohajerani, A. Oghalaie, S. Massarrat, M. Farahvash, **M. Mohammadi**. 2003. Clarithromycin Resistance in Iranian *Helicobacter pylori* Strains; Is it a Drug of Choice for Iran? *International Journal of Medical Microbiology*. 293 (35): 38
- ❖ **D. Doroud**, L. Zamaninia, S. Massarrat, H. Colding, L. P. Andersen, **M. Mohammadi**. 2003. Molecular analysis of *Helicobacter pylori* using RAPD-PCR fingerprinting to determine genetic diversity between Iranian and Danish strains. *International Journal of Medical Microbiology*. 293 (35): 96
- ❖ **D. Doroud** and **M. Mohammadi**. 2001. Molecular detection of antibiotic resistance in *Helicobacter pylori*. *Proceedings of Second International Biotechnology Congress*. 2: 1067-1073
- ❖ **Mohammadi M. D. Doroud**, N. Mohajerani, A. Oghalaie, H. Colding and L. P. Andersen. 2001. Enzymatic Digestion profiles of the *Helicobacter pylori* cytotoxin and its association with peptic ulcer disease. *International Journal of Medical Microbiology*. 291 (31): 33



Books

Co Author in:

Text Book of Tuberculosis, Supervised and Coordinated By: Dr. Ali Akbar Velayati.